BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Forge Therapeutics And Evotec AG Present First Efficacy Data For LpxC Inhibitor In UTI Model At ASM Microbe 2017

  June 5, 2017

   · 

  3 min read
• Drug Development

  AbbVie Release: Long-Term IMBRUVICA (ibrutinib) Efficacy And Safety Data At ASCO 2017 Show Sustained Survival Rates In Up To Four Years In Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those With

  June 5, 2017

   · 

  14 min read
• Drug Development

  Phase III Study Showed Genentech’s Alecensa (Alectinib) Reduced The Risk Of Disease Progression Or Death By More Than Half Versus Crizotinib As First-Line Treatment In A Specific Type Of Lung Cancer

  June 5, 2017

   · 

  10 min read
• Biotech Beach

  Poseida Therapeutics Presents High-Fidelity Genome Editing System For Production Of Allogeneic “Universal Donor” CAR-T Cells At ASCO Annual Meeting

  June 5, 2017

   · 

  4 min read
• Zenith Technologies Announces Issuance Of Patent For ZEN-3694 And Presentation Details At BIO International Convention

  June 5, 2017

   · 

  1 min read
• Drug Development

  NYU Langone Medical Center Release: Immunotherapy Drug Effective For Metastatic Triple Negative Breast Cancer

  June 5, 2017

   · 

  3 min read
• Drug Development

  Deciphera Reports Updated Phase I Clinical Study Results With DCC-2618 At 2017 ASCO Annual Meeting

  June 5, 2017

   · 

  4 min read
• AstraZeneca PLC’s Cancer Gamble Bears Fruit as Lynparza Stays One Step Ahead of PARP Rivals

  June 5, 2017

   · 

  7 min read
• Drug Development

  Bristol-Myers Squibb Release: Early, Durable Responses Seen With Sprycel (Dasatinib) In First- And Second-Line Treatment Of Pediatric Patients With Chronic Myeloid Leukemia In Chronic Phase (CP-CML)

  June 5, 2017

   · 

  2 min read
• Drug Development

  Seres Therapeutics Announces Completion Of Enrollment For SER-287 Phase IIb Study In Patients With Ulcerative Colitis

  June 5, 2017

   · 

  7 min read